Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swati Garg

Showing results (91-100 of 92) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 92 results.
Lancet (London, England)|January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialStephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Nature Communications|December 21, 2017
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemiaDaniel B Lipka, Tania Witte, Reka Toth, et al.
Pageof 10

Showing results (91-100 of 92) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 92 results.
Lancet (London, England)|January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialStephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Nature Communications|December 21, 2017
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemiaDaniel B Lipka, Tania Witte, Reka Toth, et al.
Pageof 10